Ambition to bring a steady stream of high-impact diagnostic tests to market
USD 1.8bn serviceable market with 5-10% annual growth
2 ‘blockbuster’ tests in market and product development
Team with proven track-record and industry expertise
The growing diagnostics market puts increasing pressure on clinical laboratory efficiency. However, many of the existing, clinically relevant biomarkers are available only on slow and inefficient platforms. Gentian’s solution is to utilise PETIA (Particle-Enhanced Turbidimetric Immunoassays), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers.
Gentian’s portfolio of high-impact diagnostic tests targets several large and growing disease areas such as infections and inflammation, kidney failure and congestive heart failure. The company has four established products – Cystatin C, fCAL® turbo, Canine CRP and fPELA® turbo – that contributed to 30% annual revenue growth in 2019-2023. The most recent launch in Q3 2023 of Retinol-Binding Protein (RBP) will support growth for this category. In addition, GCAL® has been launched and is in market development while NT-proBNP is in the product development phase – with the two latter having potential to become growth accelerators. The company also has undisclosed projects in exploration and ‘proof of concept’ phases.
In 2021, Gentian announced a long-term ambition to generate an estimated annual revenue of NOK 1.0 billion in 5-7 years, dependent on the timing of NT-proBNP launch yet to be concluded. In comparison, total revenue was NOK 111 million in 2022. The company’s roadmap for long-term growth and value creation is founded on six strategic pillars:
*5 established tests, 1 in market development and further 1 in product development.
** Dependent on timing of NT-proBNP launch
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.